{"id":"clm_CF81367A05A7","entity":"vertex-pharmaceuticals","predicate":"quarterly_research_and_development","value":"603,100,000 United States dollar","value_json":{"fp":"Q1","fy":2022,"accn":"0000875320-22-000014","form":"10-Q","filed":"2022-05-06","period":"Q1 FY2022","concept":"us-gaap:ResearchAndDevelopmentExpense"},"valid_from":"2022-03-31","valid_to":null,"published":"2022-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly research and development: 603,100,000 United States dollar\", as of 2022-03-31. Claim clm_CF81367A05A7, https://asof.is/claim/clm_CF81367A05A7, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532022000014/0000875320-22-000014-index.htm.","url":"https://asof.is/claim/clm_CF81367A05A7","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"supersedes":["clm_86D501AB2F5C"],"first_seen_at":"2026-11-08T17:02:27.400953+00:00","updated_at":"2026-11-08T17:02:27.400953+00:00","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532022000014/0000875320-22-000014-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2022","published_at":"2022-05-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2022, filed 2022-05-06"},"legend":{"dates":"valid_from: when the claim took effect (a period figure: the day its period closed). published: the earliest day a source on the record published it (a filing's filing date, a post's date; null when no source carries one). recorded: the day AsOf first held it. A figure can take effect weeks before it is published.","citation":"citation: how to cite the row (plain: one sentence with the value, its as-of date, the claim id and URL, the day answered and the primary source; url: the claim page; accessed: the day answered). APA and BibTeX forms are on the claim page.","why_not":{},"checked_by":{"sec-filing":"parsed from the SEC filing"}}}